Cite

HARVARD Citation

    Musso, G. et al. (2019). Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials. BMJ. p. . [Online]. 
  
Back to record